Gastric Cancer (Helicobacter pylori)
Overview
Plain-Language Overview
Gastric Cancer (Helicobacter pylori) is a type of cancer that starts in the stomach, which is part of the digestive system. It often develops after long-term infection with the bacteria Helicobacter pylori, which causes inflammation and damage to the stomach lining. This cancer can cause symptoms like abdominal pain, weight loss, and difficulty swallowing. It affects how the stomach functions, leading to problems with digestion and nutrient absorption. Early stages may have no symptoms, making it hard to detect without medical tests. If untreated, it can spread to other parts of the body and become life-threatening. Understanding this condition helps in recognizing the importance of stomach health and infection control.
Clinical Definition
Gastric Cancer (Helicobacter pylori) is a malignant neoplasm arising from the gastric mucosa, primarily caused by chronic infection with Helicobacter pylori. The infection induces chronic gastritis, leading to atrophic gastritis, intestinal metaplasia, and eventually dysplasia and carcinoma. The most common histologic type is adenocarcinoma, which can be classified into intestinal and diffuse types. This cancer is clinically significant due to its high mortality rate and late presentation with symptoms such as weight loss, epigastric pain, and early satiety. Risk factors include dietary factors, smoking, and genetic predisposition. The pathogenesis involves bacterial virulence factors like CagA and VacA that promote inflammation and genetic mutations in gastric epithelial cells.
Inciting Event
Initial colonization of gastric mucosa by Helicobacter pylori triggers chronic gastritis.
Persistent mucosal inflammation leads to progressive mucosal damage and metaplasia.
Dietary carcinogen exposure may synergize with infection to initiate neoplastic transformation.
Latency Period
Decades-long latency from initial H. pylori infection to development of gastric cancer is typical.
Progression from chronic gastritis to carcinoma often takes 20-40 years.
Symptomatic cancer usually appears after precancerous changes have developed over many years.
Diagnostic Delay
Nonspecific early symptoms such as dyspepsia and mild epigastric discomfort lead to delayed suspicion.
Overlap with benign gastric conditions like gastritis or peptic ulcer disease causes misattribution.
Lack of early screening in asymptomatic high-risk individuals delays diagnosis until advanced stages.
Limited access to endoscopy in some populations contributes to late detection.
Clinical Presentation
Signs & Symptoms
Progressive epigastric pain or discomfort is a common presenting symptom.
Early satiety due to impaired gastric emptying.
Unintentional weight loss reflecting malignancy and cachexia.
Nausea and vomiting, especially if gastric outlet obstruction develops.
Occult or overt gastrointestinal bleeding leading to anemia.
History of Present Illness
Progressive epigastric pain or discomfort often worsens after meals.
Early satiety and weight loss develop as the tumor grows and impairs gastric function.
Nausea, vomiting, and anorexia may occur in advanced disease.
Occult gastrointestinal bleeding can cause iron deficiency anemia and fatigue.
Symptoms typically worsen over months to years before diagnosis.
Past Medical History
Chronic H. pylori gastritis or previous peptic ulcer disease increases risk.
History of gastric intestinal metaplasia or dysplasia indicates precancerous changes.
Previous partial gastrectomy for benign disease predisposes to cancer in the gastric remnant.
Long-term use of proton pump inhibitors may alter gastric environment but has unclear cancer risk impact.
Family History
First-degree relatives with gastric cancer increase individual risk significantly.
Hereditary diffuse gastric cancer syndrome caused by CDH1 mutations leads to early-onset disease.
Familial adenomatous polyposis and Lynch syndrome are associated with increased gastric cancer risk.
Family history of gastric intestinal metaplasia or dysplasia suggests inherited susceptibility.
Physical Exam Findings
Palpable abdominal mass in advanced gastric cancer cases.
Virchow's node (left supraclavicular lymphadenopathy) indicating metastatic spread.
Sister Mary Joseph nodule (periumbilical metastasis) as a sign of peritoneal carcinomatosis.
Abdominal tenderness or distension due to tumor or ascites.
Signs of anemia such as pallor from chronic blood loss.
Diagnostic Workup
Diagnostic Criteria
Diagnosis of gastric cancer requires upper endoscopy with biopsy of suspicious lesions for histopathological confirmation. Key findings include irregular mucosal masses, ulcerations, or nodules on endoscopy. Histology typically shows adenocarcinoma cells with gland formation or signet ring cells in diffuse type. Imaging such as CT scan is used for staging but not diagnosis. Serologic tests for Helicobacter pylori support the etiologic association but do not confirm cancer.
Pathophysiology
Key Mechanisms
Chronic inflammation induced by Helicobacter pylori infection leads to gastric mucosal damage and increased cellular turnover.
Atrophic gastritis and intestinal metaplasia result from prolonged mucosal injury, creating a precancerous environment.
Genetic mutations in tumor suppressor genes (e.g., TP53) and oncogenes promote malignant transformation of gastric epithelial cells.
Altered gastric acid secretion due to mucosal damage facilitates bacterial overgrowth and further mucosal injury.
Immune evasion by H. pylori allows persistent infection and ongoing inflammation.
| Involvement | Details |
|---|---|
| Organs | Stomach is the organ affected by chronic H. pylori infection leading to gastritis, atrophy, intestinal metaplasia, and eventual gastric cancer. |
Liver may be involved in metastatic spread or affected by chemotherapy toxicity in advanced gastric cancer. | |
| Tissues | Gastric mucosa is the primary site of chronic inflammation and neoplastic transformation in H. pylori-associated gastric cancer. |
Lymphoid tissue in the gastric mucosa expands in response to H. pylori infection, sometimes forming mucosa-associated lymphoid tissue (MALT). | |
| Cells | Gastric epithelial cells undergo malignant transformation in gastric cancer often triggered by chronic inflammation from H. pylori infection. |
Neutrophils infiltrate the gastric mucosa during H. pylori infection, contributing to chronic inflammation and tissue damage. | |
T lymphocytes mediate immune response against H. pylori but may also promote chronic gastritis and carcinogenesis. | |
| Chemical Mediators | Interleukin-8 (IL-8) is elevated in H. pylori infection, recruiting neutrophils and sustaining chronic gastric inflammation. |
CagA protein from H. pylori disrupts host cell signaling, promoting oncogenic transformation of gastric epithelial cells. | |
Tumor necrosis factor-alpha (TNF-α) contributes to chronic inflammation and may facilitate progression to gastric cancer. |
Treatments
Pharmacological Treatments
Triple Therapy (Proton Pump Inhibitor + Clarithromycin + Amoxicillin or Metronidazole)
- Mechanism:
Eradicates Helicobacter pylori infection by combining acid suppression with antibiotics targeting bacterial protein synthesis and DNA replication.
- Side effects:
Gastrointestinal upset
Taste disturbance
Antibiotic-associated diarrhea
- Clinical role:
First-line
Bismuth Quadruple Therapy (Bismuth Subsalicylate + Proton Pump Inhibitor + Tetracycline + Metronidazole)
- Mechanism:
Combines mucosal protective agent with acid suppression and multiple antibiotics to overcome resistant H. pylori strains.
- Side effects:
Dark stools
Nausea
Photosensitivity
- Clinical role:
Second-line
Chemotherapy (e.g., 5-Fluorouracil, Cisplatin)
- Mechanism:
Targets rapidly dividing gastric cancer cells by interfering with DNA synthesis and inducing apoptosis.
- Side effects:
Myelosuppression
Nausea and vomiting
Nephrotoxicity
- Clinical role:
Adjunctive
Non-pharmacological Treatments
Surgical resection such as subtotal or total gastrectomy is performed for localized gastric cancer to remove tumor burden.
Endoscopic surveillance and biopsy are used for early detection and diagnosis of gastric mucosal changes associated with H. pylori infection.
Nutritional support and symptom management improve quality of life in advanced gastric cancer.
Prevention
Pharmacological Prevention
Eradication therapy for Helicobacter pylori using triple or quadruple antibiotic regimens.
Proton pump inhibitors to reduce gastric acid and promote mucosal healing in at-risk patients.
No established chemopreventive agents specifically approved for gastric cancer prevention.
Non-pharmacological Prevention
Screening endoscopy in high-risk populations to detect premalignant lesions early.
Dietary modifications including reduced salt intake and increased consumption of fruits and vegetables.
Smoking cessation to lower gastric cancer risk.
Avoidance of known carcinogens such as nitrosamines in preserved foods.
Regular surveillance of patients with chronic atrophic gastritis or intestinal metaplasia.
Outcome & Complications
Complications
Gastric outlet obstruction from tumor growth.
Upper gastrointestinal bleeding causing anemia or hemorrhagic shock.
Peritoneal carcinomatosis leading to ascites and bowel obstruction.
Metastatic spread to liver, lungs, and lymph nodes.
Malnutrition and cachexia due to impaired intake and systemic effects.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Gastric Cancer (Helicobacter pylori) versus Gastric lymphoma
Gastric Cancer (Helicobacter pylori) | Gastric lymphoma |
|---|---|
Adenocarcinoma with glandular formation and mucin production | Monoclonal lymphoid infiltrate with lymphoepithelial lesions |
Positive cytokeratin staining indicating epithelial origin | Positive immunohistochemistry for CD20 or other B-cell markers |
Requires surgical resection and/or chemotherapy with poor response to antibiotics alone | Often responds to chemotherapy and eradication of Helicobacter pylori |
Gastric Cancer (Helicobacter pylori) versus Peptic ulcer disease
Gastric Cancer (Helicobacter pylori) | Peptic ulcer disease |
|---|---|
Chronic Helicobacter pylori infection with gastric mass or ulcerating tumor | History of NSAID use or Helicobacter pylori infection without mass lesion |
Irregular gastric wall thickening with mass lesion on endoscopy or imaging | Well-defined mucosal ulcer without mass or wall thickening |
Progressive weight loss and persistent pain not relieved by antacids | Pain typically improves with food or antacids |
Gastric Cancer (Helicobacter pylori) versus Gastroesophageal reflux disease (GERD)
Gastric Cancer (Helicobacter pylori) | Gastroesophageal reflux disease (GERD) |
|---|---|
Iron deficiency anemia due to chronic bleeding from tumor | Normal hemoglobin and no evidence of anemia |
Progressive dysphagia and weight loss | Intermittent heartburn and regurgitation symptoms |
Ulcerated or nodular mass lesion on endoscopy | No mass or ulceration on endoscopy, only mucosal erythema |
Gastric Cancer (Helicobacter pylori) versus Gastric adenoma
Gastric Cancer (Helicobacter pylori) | Gastric adenoma |
|---|---|
Invasive adenocarcinoma with stromal invasion | Benign glandular proliferation with low-grade dysplasia |
Biopsy shows invasive carcinoma cells | No evidence of invasion on biopsy |
Symptomatic with weight loss, anemia, or obstruction | Usually asymptomatic or incidental finding |
Gastric Cancer (Helicobacter pylori) versus Ménétrier disease
Gastric Cancer (Helicobacter pylori) | Ménétrier disease |
|---|---|
Focal or diffuse mass lesion with irregular mucosa | Giant hypertrophic gastric folds without discrete mass |
Anemia and positive tumor markers in some cases | Hypoproteinemia and hypoalbuminemia due to protein loss |
Progressive weight loss and gastrointestinal bleeding | Chronic protein-losing gastropathy with edema |